论文部分内容阅读
目的:分析探讨TAC方案,即联合应用多西紫杉醇、表柔比星、环磷酰胺在乳腺癌新辅助化疗中的作用。方法:对我院收治的72例乳腺癌患者在手术前实施TAC方案新辅助化疗,分析患者化疗之后的临床总有效率、毒副作用手术效果。结果:72例乳腺癌患者中18例的病理得到完全的缓解(CR),41例达到部分缓解(PR),病情稳定(SD)的有7例,进展(PD)6例。治疗总有效率为81.94%;患者的毒副作用主要表现为骨髓抑制,白细胞减少的发生率为80.56%,此外还有部分患者出现不同程度的消化道症状和肝功能损害等毒副作用。手术后死亡9例,局部出现复发6例,远处转移17例,3年间的生存率为87.5%。结论:实施TAC新辅助化疗方案能够改善乳腺癌的临床缓解率,延长患者的生存期。
Objective: To investigate the role of TAC regimen in combination with docetaxel, epirubicin and cyclophosphamide in neoadjuvant chemotherapy of breast cancer. Methods: 72 cases of breast cancer patients treated in our hospital before the implementation of TAC regimen neoadjuvant chemotherapy, analysis of patients after chemotherapy, the total effective rate of toxic and side effects of surgical effects. RESULTS: Eighteen patients with breast cancer achieved complete remission (CR), 41 achieved partial response (PR), 7 had stable disease (SD), and 6 had progression (PD). The total effective rate of treatment was 81.94%. The side effects of the patients were mainly bone marrow suppression, the incidence of leukopenia was 80.56%, in addition there were some patients with different degrees of gastrointestinal symptoms and liver damage and other toxic side effects. There were 9 deaths after surgery, 6 local recurrences and 17 distant metastases. The 3-year survival rate was 87.5%. Conclusion: The implementation of TAC neoadjuvant chemotherapy can improve the clinical remission rate of breast cancer and extend the survival of patients.